[ad_1]
Foster City, California, June 13, 2021 (Global News Service)-Terns Pharmaceuticals, Inc. (“Terns” or “Company”) (NASDAQ:Tern), a clinical-stage biopharmaceutical company that develops a combination of small molecule monotherapy and combination therapy drug candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, announcing that the company will hold a conference call and live broadcast 2021 A webcast will be held on Monday, June 14 at 8:30 AM Eastern Time (5:30 AM Pacific Time) to discuss the new top-line data of the Phase 2a LIFT study evaluating NASH patient TERN-101. Details of the webcast and conference call are as follows:
Webcast link: https://edge.media-server.com/mmc/p/2gsxxmta
Real-time conference call
Domestic calls (US/Canada toll free): (833) 665-0612
International call: (929) 517-0403
Conference Number: 7587739
After the live audio webcast, a replay will be provided on the investor page of the Terns Pharmaceuticals website at http://ir.ternspharma.com 30 days.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops a series of small molecule monotherapy and combination therapy candidates for the treatment of non-alcoholic steatohepatitis or NASH and other chronic liver diseases. Terns’ plan is based on clinical validation and complementary mechanisms of action to address the multiple liver disease processes of NASH, thereby bringing meaningful clinical benefits to patients.For more information, please visit www.ternspharma.com.
Tern contact information:
investor
Justin Wu
Investor@ternspharma.com
media
Jenna Urban
Berry Corporation Public Relations
media@ternspharma.com
[ad_2]
Source link
